


## Cenerimod

<b>Cat. No.:</b>	HY-17606		
<b>CAS No.:</b>	1262414-04-9		
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>31</sub> N <sub>3</sub> O <sub>5</sub>		
<b>Molecular Weight:</b>	453.53		
<b>Target:</b>	LPL Receptor		
<b>Pathway:</b>	GPCR/G Protein		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (220.49 mM)  
 H<sub>2</sub>O : < 0.1 mg/mL (insoluble)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.2049 mL	11.0246 mL	22.0493 mL
	5 mM	0.4410 mL	2.2049 mL	4.4099 mL
	10 mM	0.2205 mL	1.1025 mL	2.2049 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (S1P1) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an EC<sub>50</sub> of 2.7 nM.

#### IC<sub>50</sub> & Target

EC<sub>50</sub>: 2.7 nM<sup>[2]</sup>

### REFERENCES

---

[1]. WO 2016184939 A1

[2]. WO 2011007324 A1

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA